8:31AM CytRx receives recommendation from Data Safety Monitoring Committee to complete global Phase 2b clinical trial with tamibarotene as first-line treatment for non-small-cell lung cancer (CYTR) 2.19 : Co announced that the Data Safety Monitoring Committee overseeing the Company's global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer has recommended conducting the clinical trial through completion. Enrollment of at least 140 evaluable patients is expected in the first quarter of 2013.
Market Data 
Markets 
AI
